FDA Proposes Withdrawal of Amgen Autoimmune Drug Over Efficacy Concerns

The FDA's Center for Drug Evaluation and Research has proposed withdrawing approval for Amgen's drug, Tavneos, after it failed to demonstrate the necessary clinical effectiveness. The regulatory move follows the identification of manipulated data within the ADVOCATE clinical trial and the discovery of untrue statements in the initial application. Adding to the severity of the situation, new postmarketing data has emerged linking the drug to reports of serious liver injuries. This development represents a significant blow to Amgen, as it combines concerns over data integrity with critical patient safety risks. Investors are closely monitoring the impact on the company's biotech portfolio, as the FDA reinforces its rigorous stance on drug transparency and efficacy standards.